Evaluation of henipavirus chemical inactivation methods for the safe removal of samples from the high-containment PC4 laboratory.


Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
12 2021
Historique:
received: 21 07 2021
revised: 05 09 2021
accepted: 09 09 2021
pubmed: 17 9 2021
medline: 22 3 2022
entrez: 16 9 2021
Statut: ppublish

Résumé

Henipaviruses, Hendra (HeV) and Nipah (NiV), are highly pathogenic zoonotic agents that pose a serious health risk to human life, and as such are restricted to physical containment 4 (PC4) laboratories. For further analysis of virus-infected biological specimens, it is necessary to ensure absolute inactivation of any infectious virus present before removal from the PC4 laboratory. To evaluate the inactivation of HeV and NiV within infected samples, two chemical inactivation methods were assessed. Henipavirus-infected cell monolayers treated with 4 % paraformaldehyde (PFA) showed the complete inactivation of infectious virus, with an inactivation period of 15 min resulting in more than 8-log decrease in infectious titre. NiV-infected tissue samples treated with 10 % neutral-buffered formalin (NBF) showed a complete reduction of infectious virus in 7/8 ferret organs incubated for 24 h, with the remaining tissue demonstrating complete virus inactivation after 48 h. The chemical inactivation methods described herein evaluated two simple methods of henipavirus inactivation, resulting in the complete inactivation of infectious virus - an essential requirement for the safe removal and handling of biological samples from the PC4 laboratory.

Identifiants

pubmed: 34530012
pii: S0166-0934(21)00226-3
doi: 10.1016/j.jviromet.2021.114287
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114287

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Sarah J Edwards (SJ)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia.

Sarah Caruso (S)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia.

Willy W Suen (WW)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia.

Sarah Jackson (S)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia.

Brenton Rowe (B)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia.

Glenn A Marsh (GA)

Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Centre for Disease Preparedness, 5 Portarlington Road, East Geelong, VIC, 3219, Australia. Electronic address: Glenn.Marsh@csiro.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH